Evidence map›Paper›PMID 36457846›Full record

ArticleMaterials today. Bio2022

IGF2BP3 is an essential N

Xin Xu, Jiangtao Cui, Hong Wang, Lifang Ma, Xiao Zhang, Wanxin Guo, Xiangfei Xue, Yikun Wang, Shiyu Qiu, Xiaoting Tian and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. mActa pharmaceutica Sinica. B · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Xin XuDepartment of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Jiangtao CuiDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Hong WangSchool of Public Health, Shanghai Jiao Tong University School of Medicine, 200025, China.
Lifang MaDepartment of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Xiao ZhangShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Wanxin GuoShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Xiangfei XueDepartment of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Yikun WangDepartment of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Shiyu QiuShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Xiaoting TianShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Yayou MiaoShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Mengyi WuShanghai University of Traditional Chinese Medicine, 201203, China.
Yongchun YuShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Yunhua XuShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, PR China.
Jiayi WangDepartment of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
Yongxia QiaoSchool of Public Health, Shanghai Jiao Tong University School of Medicine, 200025, China.
Shanghai Jiao Tong University · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A lack of promising targets leads to poor prognosis in patients with lung adenocarcinoma (LUAD). Therefore, it is urgent to identify novel therapeutic targets. The importance of the N

Indexed as

ACSL3, acyl-CoA synthetase long chain family member 3ALKBH5, alkB homolog 5ELISA, enzyme-linked immunosorbent assayFerroptosisFTH1, ferritin heavy chain 1FTO, fat mass-and obesity-associated geneGPX4, glutathione peroxidase 4HNRNPA2B1, heterogeneous nuclear ribonucleoprotein A2/B1IB, immunoblottingIGF2BP3, insulin-like growth factor 2 mRNA binding protein 3IHC, immunohistochemistryLUAD, lung adenocarcinomaLung adenocarcinomam6A, N6-methyladenosinem6A readerm6A RNA methylationMDA, malondialdehydeMETTL14, methyltransferase-like 14METTL3, methyltransferase-like 3PKM, pyruvate kinase M1/2qRT-PCR, quantitative reverse transcription PCRRBM15, RNA binding motif protein 15ROS, reactive oxygen speciesSLC3A2, solute carrier family 3 member 2Therapeutic targetTMA, tissue microarray assayVIRMA, vir-like m6A methyltransferase associatedWTAP, Wilms' tumor 1-associating proteinYTHDF2, YTH domain family 2ZC3H13, zinc finger CCCH-type containing 13

Identifiers

PMID36457846
PMCPMC9707255
OpenAlexW4310066308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.